ROPEGINTERFERON ALFA-2B IS EFFECTIVE AND SAFE IN ESSENTIAL THROMBOCYTHEMIA PATIENTS LACKING CYTOREDUCTIVE TREATMENT OPTIONS INDEPENDENT OF TREATMENT HISTORY AND RISK GROUP

Authors
Category Primary study
Conference31st Congress of the European Hematology Association Congress, EHA 2026
Year 2026
This article has no abstract
Epistemonikos ID: 5d3a803b8a36b7c4c18c4819ed5730234e059905
First added on: Aug 08, 2026